NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Remdesivir

Last Revision: April 19, 2021.

Estimated reading time: 1 minute

CASRN: 1809249-37-3

image 394558061 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of remdesivir during breastfeeding. Remdesivir is given intravenously because it is poorly absorbed orally, so infants are not likely to absorb clinically important amounts of the drug from milk. In addition, a newborn infants have received intravenous remdesivir therapy for Ebola with no serious adverse drug reactions.[1,2] Given this limited information, it does not appear that mothers receiving remdesivir need to avoid nursing, but until more data are available, remdesivir should be used with careful infant monitoring during breastfeeding.[3] The most common adverse effects reported after intravenous infusion include elevated aminotransferase and bilirubin levels and other liver enzyme elevations, diarrhea, rash, renal impairment and hypotension.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Dörnemann J, Burzio C, Ronsse A, et al. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis. 2017;215:171–4. [PMC free article: PMC5583641] [PubMed: 28073857]
2.
Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–303. [PubMed: 31774950]
3.
Aleissa MM, Silverman EA, Paredes Acosta LM, et al. New perspectives on antimicrobial agents: Remdesivir treatment for COVID-19. Antimicrob Agents Chemother. 2020;65:e01814–20. [PMC free article: PMC7927874] [PubMed: 33139290]

Substance Identification

Substance Name

Remdesivir

CAS Registry Number

1809249-37-3

Drug Class

Breast Feeding

Lactation

Antimetabolites

Antiviral Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...